TABLE 3.
JAK/STAT inhibitors are used in combination with other drugs.
| Agent | Disease(s) | Phase | Status* | ClinicalTrials.gov identifier(s) |
|---|---|---|---|---|
| Ruxolitinib + Chidamide | Peripheral Blood Stem Cell Transplantation | Phase 2 | Recruiting | NCT05088226 |
| NCT04582604 | ||||
| Ruxolitinib + Radiation and Temozolomide | Glioma | Phase 1 | Active, not recruiting | NCT03514069 |
| Ruxolitinib + Trastuzumab | Metastatic HER2 Positive Breast Cancer | Phase 1/2 | Completed | NCT02066532 |
| Itacitinib + Everolimus | Classical Hodgkin Lymphoma | Phase 1/2 | Recruiting | NCT03697408 |
| Itacitinib + Low-Dose Ruxolitinib | Myeloproliferative Neoplasms (MPN) | Phase 2 | Completed | NCT03144687 |
| Itacitinib + Osimertinib | Non-Small Cell Lung Cancer | Phase 1/2 | Active, not recruiting | NCT02917993 |
| Itacitinib + Alemtuzumab | T-Cell Prolymphocytic Leukemia | Phase 1 | Recruiting | NCT03989466 |
| Itacitinib + Ibrutinib | Diffuse Large B-Cell Lymphoma | Phase 1/2 | Completed | NCT02760485 |
| Itacitinib + Corticosteroids | Acute Graft-versus-host disease | Phase 3 | Completed | NCT03139604 |
| Itacitinib + Gemcitabine and Nab-Paclitaxel | Pancreatic Cancer | Phase 1/2 | Completed | NCT01858883 |
| Itacitinib + Dabrafenib and Trametinib | Melanoma | Phase 1 | Active, not recruiting | NCT03272464 |
| Itacitinib + Pembrolizumab | Colorectal Cancer | Phase 1 | Completed | NCT02646748 |
| Fedratinib + Decitabine | Myeloproliferative Neoplasms (MPN) | Phase 1 | Recruiting | NCT05524857 |
| Fedratinib + Nivolumab | Myelofibrosis | Phase 2 | Recruiting | NCT05393674 |
| Decitabine + Ruxolitinib or Fedratinib | Accelerated/Blast Phase Myeloproliferative Neoplasms | Phase 2 | Recruiting | NCT04282187 |
| Filgotinib + Methotrexate | Rheumatoid Arthritis | Phase 3 | Completed | NCT02886728 |
| NCT02889796 | ||||
| Upadacitinib + Methotrexate | Rheumatoid Arthritis | Phase 3 | Recruiting | NCT05121298 |
| Upadacitinib + Corticosteroids | Atopic Dermatitis | Phase 3 | Completed | NCT03661138 |
| Upadacitinib + Elsubrutinib | Systemic Lupus Erythematosus (SLE) | Phase 2 | Completed | NCT03978520 |
| Lestaurtinib + Chemotherapy | Acute Lymphoblastic Leukemia | Phase 3 | Active, not recruiting | NCT00557193 |
| Upadacitinib + Methotrexate | Rheumatoid Arthritis | Phase 2 | Completed | NCT01960855 |
| Danvatirsen + Tremelimumab | Diffuse large B-cell lymphoma | Phase 1 | Completed | NCT02549651 |